Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: A necessity, not an issue for debate

Intensive Care Medicine

Volumn 29, Issue 2, 2003, Pages 147-149

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; PNEUMONIA; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PUBLICATION; REGRESSION ANALYSIS; RISK FACTOR; SAMPLE SIZE; SCORING SYSTEM; SEPSIS; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VENTILATOR;

EID: 0037302917     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1614-x     Document Type: Editorial

References (18)

1. Rano A, Agusti C, Benito N, Rovira M, Angrill J, Pumarola T, Torres A (2002) Prognostic factors of non-HIV immunocompromised pulmonary infiltrates. Chest 122:253-261
2. Shorr AF, Kollef MH (2002) The quick and the dead. The importance of rapid evaluation of infiltrates in the immunocompromised patient. Chest 122:9-12
3. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 115:462-474
4. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC (1997) Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685
5. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar AE, Jimenez-Jimenez FJ, Perez-Paredes C, Orti-Leyba C (2002) Impact on the outcome of adequate empirical antibiotherapy in patients admitted to the ICU by sepsis. Crit Care Med (in press)
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
7. Alvarez-Lerma F (1996) Modifications of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 22:387-394
8. Rello J, Gallego M, Mariscal D, Sonora R, Valles J (1997) The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156:196-200
9. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C (1999) The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. Am J Respir Crit Care Med 159:1249-1256
10. Kollef MH, Ward S (1998) The influence of mini-BAL cultures on patient outcomes. Implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412-420
11. McGarvey RN, Harper JJ (1993) Pneumonia mortality reduction and quality improvement in a community hospital. QRB Qual Rev Bull 19:124-130
12. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D (2001) Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 110:451-457
13. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH (2001) Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 29:1109-1115
14. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in ICU setting. Chest 118:146-155
15. Namias N, Samiian L, Nino D, Shirazi E, O'Neill K, Kett DH, Ginzburg E, McKenney MG, Sleeman D, Cohn SM (2000) Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma Injury Infect Crit Care 49:638-645
16. Rello J, Sa Borges M, Correa H, Leal SR, Baraibar J (1999) Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 160:608-613
17. Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C (1998) Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 157:531-539
18. Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134:298-314